MGX Metagenomi Inc.
Price (delayed)
$1.33
Market cap
$49.72M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.36
Enterprise value
$62.86M
We are a precision genetic medicines company committed to developing curative therapeutics for patients using our proprietary, comprehensive metagenomics-derived genome editing toolbox. Genetic diseases are caused by a diverse set
Highlights
Metagenomi's EPS has soared by 88% YoY and by 69% from the previous quarter
MGX's quick ratio has surged by 69% year-on-year and by 11% since the previous quarter
The revenue is up by 17% year-on-year but it has declined by 5% since the previous quarter
The company's gross profit rose by 17% YoY but it fell by 5% QoQ
The net income has declined by 14% year-on-year and by 6% since the previous quarter
The equity has declined by 8% since the previous quarter
Key stats
What are the main financial stats of MGX
Market
Valuations
Earnings
Shares outstanding
37.38M
Market cap
$49.72M
Enterprise value
$62.86M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.21
Price to sales (P/S)
0.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.2
Revenue
$52.3M
Gross profit
$52.3M
Operating income
-$88.9M
Net income
-$78.06M
EBIT
-$83.57M
EBITDA
-$73.52M
Free cash flow
-$112.19M
Per share
Balance sheet
Liquidity
EPS
-$2.36
EPS diluted
-$2.36
Free cash flow per share
-$3.4
Book value per share
$6.28
Revenue per share
$1.58
TBVPS
$9.83
Total assets
$324.6M
Total liabilities
$89.74M
Debt
$45.78M
Equity
$234.86M
Working capital
$220.65M
Debt to equity
0.19
Current ratio
6.91
Quick ratio
6.83
Net debt/EBITDA
-0.18
Margins
Efficiency
Dividend
EBITDA margin
-140.6%
Gross margin
100%
Net margin
-149.3%
Operating margin
-170%
Return on assets
-21%
Return on equity
-30.1%
Return on invested capital
-27.2%
Return on capital employed
-29.1%
Return on sales
-159.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MGX stock price
How has the Metagenomi stock price performed over time
Intraday
0.76%
1 week
-16.35%
1 month
-35.12%
1 year
-87.04%
YTD
-63.16%
QTD
-2.21%
Financial performance
How have Metagenomi's revenue and profit performed over time
Revenue
$52.3M
Gross profit
$52.3M
Operating income
-$88.9M
Net income
-$78.06M
Gross margin
100%
Net margin
-149.3%
The revenue is up by 17% year-on-year but it has declined by 5% since the previous quarter
The company's gross profit rose by 17% YoY but it fell by 5% QoQ
The net income has declined by 14% year-on-year and by 6% since the previous quarter
Metagenomi's operating income has decreased by 13% YoY
Growth
What is Metagenomi's growth rate over time
Valuation
What is Metagenomi stock price valuation
P/E
N/A
P/B
0.21
P/S
0.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.2
Metagenomi's EPS has soared by 88% YoY and by 69% from the previous quarter
The P/B is 70% lower than the last 4 quarters average of 0.7
The equity has declined by 8% since the previous quarter
MGX's price to sales (P/S) is 70% lower than its last 4 quarters average of 2.8
The revenue is up by 17% year-on-year but it has declined by 5% since the previous quarter
Efficiency
How efficient is Metagenomi business performance
Metagenomi's ROE has increased by 32% from the previous quarter
MGX's ROA is down by 20% YoY and by 8% QoQ
Metagenomi's ROS has decreased by 19% YoY and by 17% from the previous quarter
The ROIC has grown by 11% YoY
Dividends
What is MGX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MGX.
Financial health
How did Metagenomi financials performed over time
MGX's current ratio has surged by 71% year-on-year and by 12% since the previous quarter
MGX's quick ratio has surged by 69% year-on-year and by 11% since the previous quarter
The debt is 81% smaller than the equity
The company's debt to equity has surged by 153% YoY and by 6% QoQ
The equity has declined by 8% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.